ESR1 and breast carcinoma: On the basis of our increasing knowledge of the interactions between ER and growth factor receptor signalling, there is a rationale for combining RTK inhibitors with endocrine therapy in breast cancer, thus enhancing the efficacy of both agents (Arpino et al, 2007).